Richard K Sterling1, Steven Chiu, Kenny Snider, Daniel Nixon. 1. Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Medical Center, Richmond, VA 23298-0341, USA. rksterli@hsc.vcu.edu
Abstract
BACKGROUND: Abnormal liver enzymes (LFTs) are frequently seen in HIV patients. Because HCV and HBV overshadow other possible variables, little is known about the prevalence and predictive factors of abnormal LFTs in the absence of viral hepatitis. AIMS: To determine the prevalence and factors associated with abnormal LFTs defined as >1.25 ULN. METHODS: A retrospective analysis of HIV clinic patients was performed. Variables were determined at the time of abnormal LFTs or by history and included diabetes mellitus (DM), hypertension (HTN), dyslipidemia, HCV and HBV status, metabolic syndrome (MS), and HAART use (NRTI, NNRTI, and PI). RESULTS: Patients without HCV/HBV (n = 679/1,208) were younger, Caucasian, had a BMI >30 and had dyslipidemia. The prevalences of elevated LFTs in those without HCV/HBV were AST 20%, ALT 15%, and ALP 43% compared to 64%, 46%, and 63% in those with HCV (all P < 0.0001), and 98% were mild-moderate (grade 1-2). While AST was highly correlated with ALT, neither was associated with increased ALP. In those without HCV/HBV, increased AST was associated with HTN, HIV RNA, and absence of PI use; increased ALT was associated with HTN, HIV RNA, CD4 < 200, MS, and absence of PI use, while increased ALP was associated with age, BMI, CD4%, DM, and NRTI use. CONCLUSIONS: Mild-moderate increased liver enzymes are common in HIV patients without HCV/HBV and absence of PI use is independently associated with elevations in both AST and ALT, while features typical of hepatic steatosis (DM and BMI) are only associated with increased ALP.
BACKGROUND:Abnormal liver enzymes (LFTs) are frequently seen in HIVpatients. Because HCV and HBV overshadow other possible variables, little is known about the prevalence and predictive factors of abnormal LFTs in the absence of viral hepatitis. AIMS: To determine the prevalence and factors associated with abnormal LFTs defined as >1.25 ULN. METHODS: A retrospective analysis of HIV clinic patients was performed. Variables were determined at the time of abnormal LFTs or by history and included diabetes mellitus (DM), hypertension (HTN), dyslipidemia, HCV and HBV status, metabolic syndrome (MS), and HAART use (NRTI, NNRTI, and PI). RESULTS:Patients without HCV/HBV (n = 679/1,208) were younger, Caucasian, had a BMI >30 and had dyslipidemia. The prevalences of elevated LFTs in those without HCV/HBV were AST 20%, ALT 15%, and ALP 43% compared to 64%, 46%, and 63% in those with HCV (all P < 0.0001), and 98% were mild-moderate (grade 1-2). While AST was highly correlated with ALT, neither was associated with increased ALP. In those without HCV/HBV, increased AST was associated with HTN, HIV RNA, and absence of PI use; increased ALT was associated with HTN, HIV RNA, CD4 < 200, MS, and absence of PI use, while increased ALP was associated with age, BMI, CD4%, DM, and NRTI use. CONCLUSIONS: Mild-moderate increased liver enzymes are common in HIVpatients without HCV/HBV and absence of PI use is independently associated with elevations in both AST and ALT, while features typical of hepatic steatosis (DM and BMI) are only associated with increased ALP.
Authors: K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2000-01-01 Impact factor: 3.731
Authors: Mark S Sulkowski; Shruti H Mehta; Michael Torbenson; Nezam H Afdhal; Lisa Mirel; Richard D Moore; David L Thomas Journal: AIDS Date: 2005-03-24 Impact factor: 4.177
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren Journal: J Infect Dis Date: 2005-08-11 Impact factor: 5.226
Authors: Juan Macías; Victor Castellano; Nicolás Merchante; Rosa B Palacios; José A Mira; Carmen Sáez; José A García-García; Fernando Lozano; Jesús M Gómez-Mateos; Juan A Pineda Journal: AIDS Date: 2004-03-26 Impact factor: 4.177
Authors: Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal Journal: Hepatology Date: 2003-06 Impact factor: 17.425
Authors: P Meraviglia; M Schiavini; A Castagna; P Viganò; T Bini; S Landonio; A Danise; M C Moioli; E Angeli; M Bongiovanni; H Hasson; P Duca; A Cargnel Journal: HIV Med Date: 2004-09 Impact factor: 3.180
Authors: Caryn G Morse; Mary McLaughlin; Lindsay Matthews; Michael Proschan; Francine Thomas; Ahmed M Gharib; Mones Abu-Asab; Abigail Orenstein; Ronald E Engle; Xiaojun Hu; Richard Lempicki; Colleen Hadigan; David E Kleiner; Theo Heller; Joseph A Kovacs Journal: Clin Infect Dis Date: 2015-02-13 Impact factor: 9.079
Authors: Jennifer C Price; Eric C Seaberg; Sheila Badri; Mallory D Witt; Kristin D'Acunto; Chloe L Thio Journal: J Infect Dis Date: 2012-01-30 Impact factor: 5.226
Authors: T J Nagu; M Kanyangarara; C Hawkins; E Hertmark; G Chalamila; D Spiegelman; F Mugusi; W Fawzi Journal: HIV Med Date: 2012-03-14 Impact factor: 3.180
Authors: H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2016-08-01 Impact factor: 3.731